21 Mar Aptinyx reports Q4 results
Net Loss: ($14.1M) (-95.8%); Loss Per Share: ($0.42) (+69.1%); Quick Assets: $150.6M (+63.5%).
The Company initiated Phase 2a study of NYX-783 in patients with PTSD, data expected in 1H 2020.
Also, Aptinyx is nearing completion of Phase 1 study of NYX-458 in healthy volunteers with data expected in 1H 2019.
Previously: Aptinyx beats by $0.08, misses on revenue (March 21)